alexa Circulating Tumor Cells Impact Factor|OMICS International|Journal Of Cell Science And Therapy

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Circulating Tumor Cells Impact Factor

The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years. Circulating Tumor Cells (CTCs), shed into the bloodstream from primary and metastatic tumors are regarded as the liquid biopsy of cancer is an enthusiastic field of research which attracted half-a thousand publications in the recent two decades. The Circulating Tumor Cells research can be categorized into three major aspects: 1) Clinically focused on the applications of Circulating Tumor Cells as biomarkers for cancer diagnosis, progression, prognosis and therapeutics; 2) Molecular characterization of Circulating Tumor Cells to determine their clinical relevance and functional activities in tumor microenvironments; and 3) Technological investment in detection and isolation of rare Circulating Tumor Cells from peripheral blood specimens and even in vivo tracking of Circulating Tumor Cells. High Circulating Tumor Cells numbers have been correlated with increased metastasis and decreased time to relapse, which supporting the predictive values on cancer progression, prognosis and survival in several cancers. A meta-analysis of 49 eligible studies enrolling 6,825 breast cancer patients indicated Circulating Tumor Cells a stable prognostic biomarker at both earlyand metastatic stages. Such encouraging reports have directed many investigators into the search of various strategies in Circulating Tumor Cells enrichment to achieve the limit of detection at one Circulating Tumor Cells per million cells level.(John YWM, Mayur-Danny GI, Circulating Tumor Cells – Cutting Edge Research?)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on October, 2020